全文获取类型
收费全文 | 337716篇 |
免费 | 12781篇 |
国内免费 | 2043篇 |
专业分类
耳鼻咽喉 | 4731篇 |
儿科学 | 11065篇 |
妇产科学 | 10254篇 |
基础医学 | 48460篇 |
口腔科学 | 9757篇 |
临床医学 | 26449篇 |
内科学 | 60845篇 |
皮肤病学 | 7604篇 |
神经病学 | 23172篇 |
特种医学 | 15609篇 |
外国民族医学 | 101篇 |
外科学 | 49773篇 |
综合类 | 6389篇 |
一般理论 | 42篇 |
预防医学 | 25697篇 |
眼科学 | 7485篇 |
药学 | 25477篇 |
2篇 | |
中国医学 | 1009篇 |
肿瘤学 | 18619篇 |
出版年
2018年 | 5487篇 |
2017年 | 5368篇 |
2016年 | 4865篇 |
2015年 | 6788篇 |
2014年 | 6801篇 |
2013年 | 6674篇 |
2012年 | 14446篇 |
2011年 | 9709篇 |
2010年 | 5224篇 |
2009年 | 6607篇 |
2008年 | 6653篇 |
2007年 | 7564篇 |
2006年 | 7819篇 |
2005年 | 15394篇 |
2004年 | 16704篇 |
2003年 | 12218篇 |
2002年 | 7365篇 |
2001年 | 12099篇 |
2000年 | 9846篇 |
1999年 | 12304篇 |
1998年 | 2832篇 |
1997年 | 2017篇 |
1992年 | 10788篇 |
1991年 | 11091篇 |
1990年 | 11065篇 |
1989年 | 10691篇 |
1988年 | 10045篇 |
1987年 | 9674篇 |
1986年 | 9170篇 |
1985年 | 8360篇 |
1984年 | 5779篇 |
1983年 | 4844篇 |
1982年 | 2139篇 |
1981年 | 1748篇 |
1980年 | 1746篇 |
1979年 | 5830篇 |
1978年 | 3663篇 |
1977年 | 2879篇 |
1976年 | 2572篇 |
1975年 | 3736篇 |
1974年 | 4514篇 |
1973年 | 4242篇 |
1972年 | 4186篇 |
1971年 | 4014篇 |
1970年 | 3739篇 |
1969年 | 3591篇 |
1968年 | 3299篇 |
1967年 | 3093篇 |
1966年 | 2779篇 |
1965年 | 1659篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献4.
5.
6.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
7.
8.
9.
10.